Detalhe da pesquisa
1.
Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program.
Cardiovasc Diabetol
; 23(1): 63, 2024 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38341541
2.
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Lancet
; 398(10313): 1811-1824, 2021 11 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-34672967
3.
Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes.
Cardiovasc Diabetol
; 21(1): 163, 2022 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36002856
4.
Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.
Am Heart J
; 170(6): 1061-9, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26678626
5.
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.
Nat Med
; 28(3): 591-598, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35210595
6.
Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.
J Clin Pharmacol
; 49(8): 984-98, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19546250
7.
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.
J Clin Pharmacol
; 48(4): 475-84, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18303127
8.
ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.
JAMA Cardiol
; 3(5): 401-408, 2018 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29525816
9.
Comparison of speed of onset of platelet inhibition after loading doses of clopidogrel versus prasugrel in healthy volunteers and correlation with responder status.
Am J Cardiol
; 100(2): 331-6, 2007 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17631093
10.
Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis.
J Cardiovasc Pharmacol Ther
; 12(3): 205-12, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17875947
11.
Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis.
J Thorac Cardiovasc Surg
; 145(4): 1077-1082.e4, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22995726
12.
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
J Am Coll Cardiol
; 60(5): 388-96, 2012 Jul 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-22633653
13.
Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy.
J Clin Pharmacol
; 52(6): 789-97, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-21628601
14.
Clopidogrel poor responders: an objective definition based on Bayesian classification.
Platelets
; 18(6): 428-35, 2007 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17763152
15.
Stereoselective metabolism of prasugrel in humans using a novel chiral liquid chromatography-tandem mass spectrometry method.
Drug Metab Dispos
; 35(6): 917-21, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17353347
16.
Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.
J Cardiovasc Pharmacol
; 49(3): 167-73, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17414229
17.
The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects.
J Cardiovasc Pharmacol
; 47(3): 377-84, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16633079